Bcr-Abl
Gli inibitori di Bcr-Abl sono terapie mirate che inibiscono la proteina di fusione Bcr-Abl, formata a seguito della traslocazione del cromosoma Philadelphia e responsabile della leucemia mieloide cronica (CML). Questa proteina influenza anche l'angiogenesi, contribuendo alla progressione tumorale. Gli inibitori di Bcr-Abl sono cruciali nel trattamento della CML e sono oggetto di ricerca per il loro potenziale nell'inibire l'angiogenesi in vari tipi di cancro. Presso CymitQuimica, offriamo inibitori di Bcr-Abl di alta qualità per supportare la tua ricerca in biologia del cancro, angiogenesi e terapie mirate.
Trovati 129 prodotti per "Bcr-Abl".
Filtra per
Percentuale di purezza
0
100
|
0
|
50
|
90
|
95
|
100
- Prezzo più basso
- Prezzo più alto
- Purezza più bassa
- Purezza più alta
- Consegna più veloce
Imatinib Mesylate
CAS:Imatinib Mesylate (STI-571) is a tyrosine kinase receptor inhibitor with antineoplastic activity (IC50s: 0.6 μM, 0.1 μM and 0.1 μM for v-Abl, c-Kit and PDGFR,Formula:C29H31N7O·CH4SO3Purezza:98% - >99.99%Colore e forma:White SolidPeso molecolare:589.71Dasatinib
CAS:Dasatinib (BMS-354825) is a tyrosine kinase inhibitor that inhibits Src and Bcr-Abl (Ki=16/30 pM) and is orally active and ATP-competitive.Formula:C22H26ClN7O2SPurezza:99.59% - 99.86%Colore e forma:Pale-Yellow SolidPeso molecolare:488.006Lyn-IN-1
CAS:Lyn-IN-1 (Bafetinib analog) is a selective and potent dual inhibitor of Bcr-Abl and LynFormula:C30H31F3N8OPurezza:98.02% - 98.77%Colore e forma:SolidPeso molecolare:576.62Ref: TM-T11916
1mg38,00€2mg50,00€5mg79,00€1mL*10mM (DMSO)92,00€10mg117,00€25mg236,00€50mg371,00€100mg530,00€200mg770,00€Imatinib impurities3
CAS:Imatinib impurities3 is a protein kinases inhibitor with IC50 values of 6.95uM, 0.245uM, 0.139uM for ABL1 wt, KIT wt, PDGFRR wt, respectively.Formula:C24H20ClN5OPurezza:98.63%Colore e forma:SolidPeso molecolare:429.902LXH254
CAS:LXH254 is a B/C RAF inhibitor with IC50 values of 0.2 nM and 0.07 nM for inhibiting BRAF and CRAF.Cost-effective and quality-assured.Formula:C25H25F3N4O4Purezza:98.30% - 99.92%Colore e forma:White SolidPeso molecolare:502.49Ref: TM-T11898
1mg50,00€5mg115,00€1mL*10mM (DMSO)128,00€10mg175,00€25mg344,00€50mg537,00€100mg653,00€200mg898,00€500mg1.369,00€N-Desmethyl imatinib
CAS:N-Desmethyl imatinib (Imatinib metabolite N-Desmethyl imatinib) is a metabolite of Imatinib, which is a multi-target inhibitor of c-Kit, v-Abl, and PDGFR.Formula:C28H29N7OPurezza:98.60%Colore e forma:SolidPeso molecolare:479.576Ref: TM-T11641
1mg87,00€5mg166,00€1mL*10mM (DMSO)170,00€10mg303,00€25mg512,00€50mg737,00€100mg1.018,00€Bosutinib
CAS:Bosutinib (SKI-606) is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl (IC50: 1 nM) and Src (IC50: 1.2 nM) kinases.Formula:C26H29Cl2N5O3Purezza:98.98% - 99.93%Colore e forma:Yellow SolidPeso molecolare:530.446Dasatinib monohydrate
CAS:Dasatinib monohydrate, an oral SRC-kinase inhibitor, counters imatinib-resistant chronic myeloid leukemia.Formula:C22H28ClN7O3SPurezza:99.68% - >99.99%Colore e forma:White SolidPeso molecolare:506.03Nilotinib
CAS:Nilotinib (AMN107) is a Bcr-Abl tyrosine kinase inhibitor. Nilotinib has antitumor activity and may be used in CML. Cost-effective and quality-assured.Formula:C28H22F3N7OPurezza:99.89% - >99.99%Colore e forma:SolidPeso molecolare:529.52AKE-72
CAS:AKE-72 is a Pan-BCR-ABL inhibitor with anti-leukemic activity.AKE-72 inhibits the proliferation of Ba/F3 cells expressing natural BCR-ABL or its T315I mutant.Formula:C30H29F3N6OPurezza:99.91%Colore e forma:SolidPeso molecolare:546.59Ref: TM-T80676
1mg88,00€2mg129,00€5mg212,00€10mg310,00€25mg479,00€50mg642,00€100mg880,00€200mg1.161,00€SIAIS056
CAS:SIAIS056 is a BCR-ABL PROTAC degrader with a DC50 value of 0.18 nM. It inhibits the BCR-ABL signaling pathway in a time-dependent manner in K562 cells and reduces the phosphorylation levels of BCR-ABL and its downstream molecules, STAT5 and CRKL. SIAIS056 can induce the degradation of various clinically relevant BCR-ABL resistant mutants and exhibits antiproliferative activity against K562 and 32D-BCR-ABL cells. Additionally, it can cause significant tumor regression in K562 xenograft models and is applicable for leukemia research.Formula:C35H34ClN9O5S2Peso molecolare:760.29SNIPER(ABL)-020
SNIPER(ABL)-020, a Dasatinib-Bestatin conjugate via linker, inhibits ABL and targets IAP, reducing BCR-ABL protein.Formula:C44H59ClN10O8SPurezza:98%Colore e forma:SolidPeso molecolare:923.52FDA-Approved Kinase Inhibitor Library
A unique collection of xnum kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.Colore e forma:LiquidRef: TM-L1610
1mgPrezzo su richiesta10μL*10mM (DMSO)Prezzo su richiesta30μL*10mM (DMSO)Prezzo su richiesta50μL*10mM (DMSO)Prezzo su richiesta100μL*10mM (DMSO)Prezzo su richiestaKinase Inhibitor Library
A unique collection of xnum kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;Colore e forma:Odour SolidRef: TM-L1600
1mgPrezzo su richiesta10μL*10mM (DMSO)Prezzo su richiesta30μL*10mM (DMSO)Prezzo su richiesta50μL*10mM (DMSO)Prezzo su richiesta100μL*10mM (DMSO)Prezzo su richiestaP19As
CAS:P19As is a BCR-ABL PROTAC degrader based on Asciminib, with a DC50 of approximately 200 nM for the wild-type BCR-ABL protein. It is capable of degrading the T315I mutant and demonstrates strong antiproliferative activity in BaF3-BCR-ABL (T315I) cells. P19As is applicable for research in chronic myeloid leukemia and acute lymphoblastic leukemia.Formula:C47H51ClF2N12O10Peso molecolare:1017.45SNIPER(ABL)-019
SNIPER(ABL)-019, a compound that links Dasatinib (ABL inhibitor) to MV-1 (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels, exhibiting aFormula:C60H77ClN12O9SPurezza:98%Colore e forma:SolidPeso molecolare:1177.85FGFRs-IN-1
FGFRs-IN-1 (Compound A16) is an orally active inhibitor targeting FGFR1/2/3/4, with IC50 values of 2.3, 7, 11, and 163 nM respectively. It also inhibits VEGFR1/2/3, Abl, and Flt3, with IC50 values of 61, 176, 112, 26, and 353 nM. The compound shows weak inhibition of CYP enzymes. FGFRs-IN-1 reduces the expression of α-SMA and collagen I, and it inhibits epithelial-mesenchymal transition (EMT) in A549 cells stimulated by TGF-β1. Additionally, FGFRs-IN-1 demonstrates anti-inflammatory activity in mouse models of lung fibrosis induced by Bleomycin and liver fibrosis induced by CCl4.Formula:C28H26Cl2N4O3Colore e forma:SolidPeso molecolare:537.44PROTAC BCR-ABL1 ligand 1
CAS:GMB-475 is a PROTAC ligand targeting BCR-ABL1 for degradation via E3 ligase recruitment.Formula:C17H12F3N3O2Colore e forma:SolidPeso molecolare:347.29ML 2-23
ML 2-23 is a potent BCR-ABL degrader operating as a PROTAC, exhibiting selective proteasome-dependent degradation of BCR-ABL within leukemia cells [1].Formula:C47H53BrCl2N10O7SPurezza:98%Colore e forma:SolidPeso molecolare:1052.86DPH
CAS:DPH is a potent cell permeable activator of c-Abl. It shows potent enzymatic and cellular activity in stimulating c-Abl activation.Formula:C18H13FN4O2Purezza:99.65%Colore e forma:SolidPeso molecolare:336.32
